{
    "root": "5d5716f1-0fbf-48cd-bef1-f8245bd87c13",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Alprazolam",
        "suffix": {
            "text": "Extended Release"
        }
    },
    "value": "20230228",
    "ingredients": [
        {
            "name": "ALPRAZOLAM",
            "code": "YU55MQ3IZY"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "D&C YELLOW NO. 10 ALUMINUM LAKE",
            "code": "CQ3XH3DET6"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C BLUE NO. 2--ALUMINUM LAKE",
            "code": "4AQJ3LG584"
        },
        {
            "name": "INDIGOTINDISULFONATE SODIUM",
            "code": "D3741U8K7L"
        }
    ],
    "indications": "Alprazolam extended-release tablets are indicated for the treatment of panic disorder with or without agoraphobia, in adults.",
    "contraindications": "Recommended starting oral dosage is 0.5 mg to 1 mg once daily (preferably in the morning). Depending on the response, the dose may be increased at intervals of 3 to 4 days in increments of no more than 1 mg daily. ( 2.1 ) Recommended total daily dosage is 3 mg to 6 mg daily. ( 2.1 ) Swallow tablets whole; do not divide, crush, or chew. ( 2.1 ) When tapering, decrease dosage by no more than 0.5 mg every 3 days. Some patients may require an even slower dosage reduction. ( 2.2 , 5.2 ) See the Full Prescribing Information for the recommended dosage in geriatric patients, patients with hepatic impairment, and with use with ritonavir. ( 2.3 , 2.4 , 2.5 )",
    "warningsAndPrecautions": "Alprazolam extended-release tablets, USP are available as follows:\n                  \n                     0.5 mg: Each white to off-white, round tablet imprinted with  on one side and 83 on the other contains 0.5 mg of Alprazolam, USP. Tablets are supplied in bottles of 60 (NDC 0228-3083-06).\n                  \n                  \n                     1 mg: Each yellow, round tablet imprinted with on one side and 84 on the other contains 1 mg of Alprazolam, USP. Tablets are supplied in bottles of 60 (NDC 0228-3084-06).\n                  \n                  \n                     2 mg: Each peach, round tablet imprinted with  on one side and 87 on the other contains 2 mg of Alprazolam, USP. Tablets are supplied in bottles of 60 (NDC 0228-3087-06).\n                  \n                  \n                     3 mg: Each light green, round tablet imprinted with  on one side and 86 on the other contains 3 mg of Alprazolam, USP. Tablets are supplied in bottles of 60 (NDC 0228-3086-06).\n                  \n                  Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP.",
    "adverseReactions": "Alprazolam extended-release tablets are contraindicated in patients: \n                  \n                     with known hypersensitivity to alprazolam or other benzodiazepines. Angioedema has been reported [see Adverse Reactions (6.2)].\n                     \n                     \n                         taking strong cytochrome P450 3A (CYP3A) inhibitors (e.g., ketoconazole, itraconazole), except ritonavir [see Dosage and Administration (2.5), Warnings and Precautions (5.5), Drug Interactions (7.1)]."
}